Friedrich Miescher Institute for Biomedical Research, 4058 Basel, Switzerland; Faculty of Sciences, University of Basel, 4003 Basel, Switzerland.
Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland.
Stem Cell Reports. 2021 Sep 14;16(9):2107-2117. doi: 10.1016/j.stemcr.2021.07.023. Epub 2021 Aug 26.
Wilms tumor is the most widespread kidney cancer in children and frequently associated with homozygous loss of the tumor suppressor WT1. Pediatric tumorigenesis is largely inaccessible in humans. Here, we develop a human kidney organoid model for Wilms tumor formation and show that deletion of WT1 during organoid development induces overgrowth of kidney progenitor cells at the expense of differentiating glomeruli and tubules. Functional and gene expression analyses demonstrate that absence of WT1 halts progenitor cell progression at a pre-epithelialized cell state and recapitulates the transcriptional changes detected in a subgroup of Wilms tumor patients with ectopic myogenesis. By "transplanting" WT1 mutant cells into wild-type kidney organoids, we find that their propagation requires an untransformed microenvironment. This work defines the role of WT1 in kidney progenitor cell progression and tumor suppression, and establishes human kidney organoids as a phenotypic model for pediatric tumorigenesis.
肾母细胞瘤是儿童中最常见的肾癌,常与肿瘤抑制因子 WT1 的纯合缺失有关。儿科肿瘤的发生在很大程度上不能在人体中进行研究。在这里,我们开发了一种用于肾母细胞瘤形成的人类肾类器官模型,并表明在类器官发育过程中 WT1 的缺失会导致肾祖细胞的过度生长,而牺牲了分化的肾小球和肾小管。功能和基因表达分析表明,WT1 的缺失会阻止祖细胞向上皮细胞状态的进展,并重现了在具有异位肌生成的 Wilms 肿瘤患者亚组中检测到的转录变化。通过将 WT1 突变细胞“移植”到野生型肾类器官中,我们发现它们的增殖需要未转化的微环境。这项工作定义了 WT1 在肾祖细胞进展和肿瘤抑制中的作用,并建立了人类肾类器官作为儿科肿瘤发生的表型模型。